21:57 , Jun 27, 2019 |  BC Innovations  |  Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
23:33 , Jun 17, 2019 |  BC Extra  |  Company News

Sanofi shies away from neuro gene therapy programs

Changes to two partnerships this year suggest Sanofi is paring down the disease areas in which it wants to deploy gene therapy. The latest came on Monday, when Voyager Therapeutics Inc. (NASDAQ:VYGR) said it and...
20:28 , Mar 11, 2019 |  BC Extra  |  Clinical News

Axovant reports first clinical gene therapy data

After rebooting to focus exclusively on gene therapies, Axovant gained $0.21 (14%) to $1.69 on Monday after reporting its first data from its retooled pipeline. The lowest dose of its Parkinson's disease therapy, AXO-Lenti-PD, was...
20:10 , Mar 1, 2019 |  BC Week In Review  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
00:14 , Feb 23, 2019 |  BC Extra  |  Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
19:42 , Feb 1, 2019 |  BC Week In Review  |  Company News

Voyager gets $165M up front from Neurocrine for gene therapies

Voyager Therapeutics Inc. (NASDAQ:VYGR) will receive $165 million up front from Neurocrine Biosciences Inc. (NASDAQ:NBIX) in exchange for a license to four of Voyager's neurology gene therapy programs. Voyager is eligible for $1.7 billion in...
20:41 , Jan 29, 2019 |  BC Extra  |  Company News

Voyager gets $165M up front from Neurocrine for gene therapies

Voyager Therapeutics Inc. (NASDAQ:VYGR) gained $3.08 (38%) to $11.12 on Tuesday after it said it will receive $165 million up front from Neurocrine Biosciences Inc. (NASDAQ:NBIX) in exchange for a license to four of Voyager's...
21:00 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Voyager begins Phase II of PD gene therapy VY-AADC

Voyager Therapeutics Inc. (NASDAQ:VYGR) started the Phase II RESTORE-1 trial of gene therapy VY-AADC to treat Parkinson's disease patients with motor fluctuations that are refractory to medical management. The double-blind, U.S. trial is slated to...
00:37 , Nov 8, 2018 |  BC Extra  |  Company News

Phase II trial alone may not support BLA for Voyager's Parkinson's gene therapy

Voyager Therapeutics Inc. (NASDAQ:VYGR) said late Wednesday that FDA now considers a randomized Phase II trial of VY-AADC to be an "early phase exploratory study," suggesting that the Phase II trial by itself may no...
17:50 , Jul 20, 2018 |  BC Week In Review  |  Company News

PTC acquiring CNS gene therapy play Agilis

PTC Therapeutics Inc. (NASDAQ:PTCT) will acquire gene therapy company Agilis Biotherapeutics Inc. (Cambridge, Mass.), giving the rare disease company four products in development for CNS disorders. PTC will pay Agilis shareholders about $200 million up...